首页> 美国卫生研究院文献>Acta Bio Medica : Atenei Parmensis >Topical Fisionerv® is effective in treatment of peripheral neuropathic pain
【2h】

Topical Fisionerv® is effective in treatment of peripheral neuropathic pain

机译:局部用Fisionerv®可有效治疗周围神经性疼痛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Management of neuropathic pain (Neu P) is complex and difficult. Although there are several therapeutic options, treatment with Neu P is often inadequate, which led to undertreated patients. Thus, it would be desirable, for Neu P treatment, further multimechanistics approaches.Objective: The aim of the present study was to evaluate, in Neu P management, the effectiveness of “FISIONERV, a gel for topical use. Setting: This study was conducted in the “Rehabilitation Unit of N. Melli’s Hospital, Brindisi, Italy”. Patients and intervention: In this study a double-blind randomized controlled clinical trial was conducted over 8-week treatment on 58 outpatients affected by Neu P caused by lumbar sciatica or lumbar disk herniation and/or lumbar canal stenosis (31 subjects), or with carpal tunnel syndrome (27 subjects), randomly assigned to the following two groups: Group A; n=29, received (fisionerv® gel, 3 times/day) added to physiotherapy (forty minutes-daily session). Group B; n=29 received a vehicle gel (placebo, 3 times/day) added to physiotherapy (forty minutes-daily session). Measurements: Pain was assessed by a visual analogue scale (VAS). Neuropathic symptoms frequency (pain, burning, paraesthesiae and numbness) were scored at baseline and at the end of the treatment. Treatment compliance and safety were also evaluated. Results: Both groups experienced a significant reduction in VAS and neuropathic symptoms after 8-treatment weeks. However, a significant (p<0.05) improvement was observed in group A (VAS mean 5.3 (1.10) with respect to group B (VAS mean=6.17 (0.80), already after 4 weeks of treatment. A further VAS reduction was recorded at 8 treatment weeks, with significant difference between the treatments (group A: VAS mean=1.89 (0.77); group B: VAS mean=3.79 (1.20) (p<0.001). In addition, more patients of the group A, than in group B, reported an improvement of their neurophatc pain (p<0.01). No adverse drug reaction was observed. Conclusion: Use of fisionerv®, in combination with physiotherapy, resulted a useful approach to NP treatment. Clinical rehabilitation impact: These preliminary observations suggest that some interesting goals (better pain control and physical wellbeing) could be achieved by a multimodal therapy in NP patients. ()
机译:背景:神经性疼痛(Neu P)的治疗既复杂又困难。尽管有几种治疗选择,但用Neu P进行的治疗通常不足,从而导致患者治疗不足。因此,对于Neu P治疗,希望有更多的多机制方法。目的:本研究的目的是评估Neu P管理中“ FISIONERV,一种局部用凝胶”的有效性。地点:这项研究是在“意大利布林迪西N. Melli医院的康复科”进行的。患者和干预措施:在这项研究中,对58位因腰椎坐骨神经痛或腰椎间盘突出症和/或腰椎管狭窄而受Neu P影响的门诊患者进行了为期8周的双盲随机对照临床试验(31名受试者),或腕管综合症(27名受试者),随机分为以下两组:A组; n = 29,接受(凝胶,每天3次)加入物理治疗(每天40分钟)。 B组; n = 29接受了溶媒(安慰剂,每天3次)加到理疗中(每天40分钟)。测量:通过视觉模拟量表(VAS)评估疼痛。在基线和治疗结束时对神经性症状的发生频率(疼痛,灼热,感觉异常和麻木)进行评分。还评估了治疗依从性和安全性。结果:两组在8个治疗周后均经历了VAS和神经病变症状的显着减少。然而,在治疗4周后,A组(VAS均值5.3(1.10)相对于B组(VAS均值= 6.17(0.80))有显着改善(p <0.05)。 8个治疗周,不同治疗之间存在显着差异(A组:VAS平均值= 1.89(0.77); B组:VAS平均值= 3.79(1.20)(p <0.001)。 B组报告其神经相疼痛有所改善(p <0.01),未观察到药物不良反应结论:fisionerv®结合物理疗法的使用,是治疗NP的有效方法临床康复影响:这些初步观察提示通过多模式疗法治疗NP患者可以实现一些有趣的目标(更好的疼痛控制和身体健康)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号